nContact Surgical, Inc.: Interdisciplinary Convergent Approach May Represent Future for Treatment of Atrial Fibrillation
Published: Sep 22, 2010
Professor Gersak has been instrumental in developing the Convergent Procedure, a completely closed-chest surgical technique that is designed to treat all types of atrial fibrillation, the most common cardiac arrhythmia (abnormal heartbeat) affecting millions of people worldwide.
The Convergent Procedure is a combined epicardial-endocardial ablation approach. A cardiac surgeon initially creates a comprehensive bi-atrial lesion pattern through a 2.5cm abdominal incision, without chest incisions, ports, or lung deflation. The surgeon utilizes the nContact coagulation device during epicardial ablation to create continuous, linear lesions on a beating heart. Within the same setting, an electrophysiologist will then perform endocardial ablation to complete the lesion pattern and utilize mapping and diagnostics to ensure procedure endpoints are achieved.
"Cardiologists don't accept surgical ablation procedures as 'minimally invasive' if they require multiple thoracic incisions and lung deflation. As such, procedures for treating atrial fibrillation must eliminate invasive chest incisions while allowing surgeons to have direct visualization of the heart and their instruments through endoscopes," stated Professor Gersak. "This subthoracic total endoscopic 'subtle' approach to surgery is the key to adoption of the Convergent Procedure, which provides a complete interdisciplinary approach to address the tougher atrial fibrillation patient populations with improved procedure times, less patient discomfort, and quicker recovery."
At the Techno College Session, cardiac surgical leaders echoed the call for improved technologies that enable less invasive surgical approaches and precise diagnostic endpoints to predict results for atrial fibrillation procedures.
Professor Gerhard Wimmer Greinecker, Chief of Cardiac Surgery at the Heart and Vascular Center in Bad Bevensen, Germany, who chaired the atrial fibrillation session, joined Professor Gersak in support of "subtle surgery" for treating atrial fibrillation. "Techniques such as the Convergent Procedure are the future of atrial fibrillation treatment as it leaves the thoracic cavity and lungs undisturbed, while enabling the cardiac surgeon to have visibility and access to the heart. This will be an important advantage in the minds of cardiologists and patients, as the approach is thought of simply as a 'procedure' rather than surgery. Demand for 'subtle surgical approaches' will continue to drive future innovation and adoption within the atrial fibrillation market."
About nContact Surgical, Inc.
nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, continuous, bi-atrial lesions on the epicardium of a beating heart.
To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.
nContact Surgical. Inc.
1001 Aviation Parkway, Ste 400
Morrisville, NC 27560 USA
T (404) 285-0466
T (919) 466-9810
F (919) 466-9811
Kimberly Muscara/Jason Rando
The Ruth Group
T (646) 536-7011/7025
SOURCE nContact Surgical, Inc.